Svmuu reports that Chainalysis has released a report stating that as demand for gray market peptide products (such as weight loss drugs like semaglutide) grows rapidly, related suppliers and buyers are increasingly using cryptocurrencies for transactions, with leading suppliers primarily relying on Bitcoin and stablecoins.
The report shows that crypto funds flowing into this sector reached $32 million in the first quarter of 2026, a 159% increase from $12 million in the previous quarter, with the annualized scale already exceeding $100 million.
Chainalysis points out that demand for peptide products is driven by trends in medical aesthetics, health and wellness, and the popularity of GLP-1 drugs. However, since these products often involve prescription-grade compounds or unregulated substances, traditional banks and credit card processors typically restrict their transactions, prompting the market to shift towards crypto payments.
The agency also noted that some leading suppliers have adopted more professional on-chain fund management methods. Particularly among suppliers with average single deposits exceeding $1,000, the proportion of stablecoins has significantly increased, likely to mitigate the risk of large supply chain orders being affected by crypto market volatility.